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Abstract 17 
Previous studies suggested that caspofungin dose escalation against Candida species is 18 
more beneficial than currently used lower daily doses. Thus, we determined in vitro and in 19 
vivo activity of caspofungin against six wild-type C. albicans clinical isolates, the ATCC 20 
10231 strain and an echinocandin resistant strain. MIC ranges of clinical isolates in RPMI-21 
1640 with and without 50% serum were 0.125-0.25 and 0.015-0.06 mg/L, respectively. 22 
Two and three isolates showed paradoxical growth in MIC and time-kill tests, respectively, 23 
in RPMI-1640 but not in 50% serum. Caspofungin killing rate (k) in RPMI-1640 at 1 mg/L 24 
was higher than at 16 and 32 mg/L for all isolates (p<0.001). Killing rates for five of six 25 
isolates were concentration independent between 1-32 mg/L in 50% serum (p>0.05 for all 26 
comparisons), but for one isolate k value at 32 mg/L was significantly lower that at 1-16 27 
mg/L. Although k values at 1-32 mg/L showed a great variability in 50% serum (the lowest 28 
and highest k value ranges were 0.085-0.109 and 0.882-0.985 1/h, respectively), daily 3, 5 29 
and 15 mg/kg caspofungin was effective in a neutropenic murine model against all isolates, 30 
without significant differences between the effective doses. This study confirms that 31 
paradoxical growth does not affect the in vivo efficacy of caspofungin. We demonstrated 32 
that dose escalation did not increase the efficacy of caspofungin against C. albicans either 33 
in vitro or in vivo. These results are in concordance with the clinical experience that 34 
efficacy of echinocandins does not increase at larger doses. 35 
36 
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1. Introduction 37 
Echinocandins show low MIC values and concentration-dependent fungicidal or 38 
fungistatic activity against the majority of Candida species in test media RPMI-1640 and 39 
antibiotic medium 3 [1-9]. Moreover, echinocandins proved to be highly effective in the 40 
treatment of invasive infections caused by Candida species both in animal models and in 41 
clinical situations [1-4, 10, 11]. 42 
Echinocandins are increasingly used as first line agents in candidemia and other types of 43 
deep-seated life-threatening infections [1-4, 10-12]. Unfortunately, mortality rate due to 44 
invasive Candida infections is still increasing (mean mortality rate around 40% at present) 45 
[10-13]. Although the basic illness is recognized as the most important risk factor of death 46 
among severely ill patients, appropriate antifungal treatment is a key factor for clinical 47 
success [2, 4, 10-13], therefore optimizing the echinocandin therapy is an urgent challenge.  48 
As echinocandins are highly protein-bound antifungals (≥97.5%) serum or tissue proteins 49 
may alter their activity [1-5]. Both decreased and increased in vitro activities of 50 
echinocandins against Candida and Aspergillus species were demonstrated when the test 51 
medium was supplemented with 5-50% serum in the broth microdilution (BMD) MIC tests 52 
[14-18]. Time kill studies in 50% serum revealed decreased echinocandins activity against 53 
Candida species [19, 20].   54 
In our previous studies we have compared the caspofungin killing rate in RPMI-1640 and 55 
RPMI-1640 plus 50% serum against C. albicans, C. krusei and C. inconspicua isolates [19, 56 
20]. We noticed increased MIC values in RPMI-1640 plus 50% serum and concentration 57 
independent killing activity of caspofungin at 1-32 mg/L against the three species. 58 
Moreover, when the same isolates were tested with various caspofungin doses in a 59 
neutropenic murine model in cases of C. krusei and C. inconspicua no differences were 60 
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found between effective doses in decreasing the fungal kidney tissue burden [19]. Such 61 
comparisons have nor yet been performed against the most frequency isolated C. albicans.  62 
The aim of this study was to test the in vivo activity of caspofungin in a neutropenic 63 
murine model against C. albicans clinical isolates. In order to compare in vivo activity to in 64 
vitro efficacy, caspofungin killing rate in RPMI-1640 and RPMI-1640 plus 50% serum 65 
were determined. 66 
 67 
2. Materials and methods 68 
2.1. Strains 69 
We studied six randomly selected C. albicans bloodstream strains isolated in 2014 in our 70 
Laboratory (Table 1). All isolates were unique and first isolates (isolated prior to antifungal 71 
administration). Isolates were identified with conventional methods and MALDI Biotyper 72 
(Bruker, Bremen, Germany) [20]. In the preliminary experiments two isolates (10781 and 73 
34350) showed paradoxical growth (PG) in the BMD test. PG is defined as growth at 74 
supra-MICs [6, 7]. Two echinocandin resistant strains, DPL18 (F641S) and DPL20 75 
(F645P) and three ATCC type strains (C. albicans ATCC 10231, C. krusei ATCC 6258 76 
and C. parapsilosis ATCC 22019) were also evaluated in the study [20, 21]. 77 
2.2 Susceptibility testing 78 
Two test media were used, RPMI-1640 as recommended by CLSI (referred to as RPMI) 79 
and RPMI-1640 supplemented with 50% human serum from a human male, type AB, 80 
Sigma, Budapest, Hungary (referred to as 50% serum) [16-20, 22, 23]. Caspofungin 81 
(Sigma, Budapest, Hungary) MICs in RPMI and in 50% serum were determined 82 
simultaneously using the standard CLSI BMD method. Caspofungin final concentration 83 
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ranges were 0.015-32 mg/L. MICs were determined after 24 h according to the partial 84 
inhibition criterion [16-20, 23]. 85 
MIC values were also determined using Etest method (AB Biodisk, Sweden) [24]. Etest 86 
was carried out using freshly prepared RPMI 1640 agar supplemented with 2% glucose 87 
with and without 50% human serum. Etest was carried out according to the instructions of 88 
the manufacturer and the results were read after 24 hours [3, 23, 24].  89 
 90 
2.3. Time-kill studies 91 
As results for ATCC 10231 and the echinocandin resistant strain DPL20 were reported in 92 
previous studies [20], in killing studies we tested only the six C. albicans clinical isolates 93 
in the present study. Caspofungin activity was determined in RPMI-1640 with and without 94 
50% human serum at 0.25, 1, 4, 8, 16 and 32 mg/L concentrations using a starting 95 
inoculum of ~10
5
 cells/ml in a final volume of 10 ml [16-20]. Aliquots of 100 l were 96 
removed after 0, 4, 8, 12, 24 and 48 hours of incubation, tenfold serial dilutions were 97 
prepared, and samples of dilutions (4x30 l) were plated onto a single Sabouraud dextrose 98 
agar (SDA) and incubated at 35 °C for 48 hours [16-20]. All experiments were performed 99 
in both media with two repetitions.  100 
 101 
2.4. Analysis of in vitro data 102 
Caspofungin activity was defined as fungicidal when at least 99.9% reduction in viable cell 103 
count was observed as compared to the starting inoculums [6-9, 16-20, 22].  104 
Killing kinetics at the tested concentrations were analysed in both media (RPMI and 50% 105 
serum), as described previously [8, 9, 19, 20]. Briefly, an exponential equation was fitted 106 
to the mean data at each time point: Nt = N0 × e
−kt
, where Nt is the number of viable yeasts 107 
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at time t, N0 is the number of viable yeasts in the initial inoculum, k is the killing rate, and t 108 
is the incubation time. Thus killing rate represents the overall killing capability of the drug, 109 
taking into account of killing at each tested concentration. Negative k values indicate 110 
growth and positive k values indicate killing. The goodness of fit for each isolate was 111 
assessed by the r
2 
value (r
2
>±0.8) [19, 20]. The mean times to achieve the fungicidal 112 
endpoint (T99.9=3/k) were calculated from the k values for each isolate and concentrations 113 
in both media [8, 9, 19]. 114 
Killing kinetics among isolates was compared using one-way ANOVA with Tukey’s post-115 
testing in either RPMI-1640 or 50% serum. The effect of the same drug concentration in 116 
RPMI-1640 and 50% serum was analysed using T test (with Welch's correction, where 117 
appropriate) [19, 20]. 118 
2.5. In vivo studies  119 
Groups of seven to eight female BALB/c mice (20-22 g) were immunosuppressed with 120 
four doses of cyclophosphamide, i.e. 4 days before infection (150 mg/kg), 1 day before 121 
infection (100 mg/kg), 2 days postinfection (100 mg/kg) and 5 days postinfection (100 122 
mg/kg) [16, 19, 20]. The Guidelines for the Care and Use of Laboratory Animals was 123 
strictly followed during maintenance of the animals; experiments were approved by the 124 
Animal Care Committee of the University of Debrecen (permission no. 12/2008). All six 125 
clinical isolates as well as the ATCC 10231 and the DPL20 strains were tested in in vivo 126 
model. Mice were inoculated intravenously through the lateral tail vein with an infectious 127 
dose of 7.5x10
4
 CFU/mouse. Confirmation of inoculum density was performed using 128 
plating serial dilutions onto SDA plates [16, 19, 21]. 129 
Five-day intraperitoneal treatment with daily 1, 2, 3, 5 and 15 mg/kg caspofungin 130 
(Cancidas, commercial preparation) was started after 24 hours [16, 19, 21]. This dosing 131 
strategy was based on previous pharmacokinetic studies and on previous results of our 132 
7 
 
study group [16, 19, 21, 25-28]. On day six after infection, all mice were sacrificed; the 133 
kidneys were removed (both), weighed and homogenized aseptically. Homogenates were 134 
diluted tenfold; aliquots of 0.1 ml of the undiluted and diluted (1:10) homogenates were 135 
plated onto SDA plates and incubated at 35 °C for 48 h. The lower limit of detection was 136 
50 CFU/g of tissue. Statistical analysis of the kidney burden was performed using the 137 
Kruskal-Wallis test with Dunn’s post-test for multiple comparisons [16, 19, 21]. 138 
 139 
3. Results 140 
3.1. In vitro studies 141 
3.1.1. MIC results in RPMI-1640  142 
MIC values are presented in Table 1. Clinical isolates as well as the ATCC type strains 143 
were susceptible to caspofungin according to the revised CLSI breakpoints in RPMI in the 144 
BMD tests [3, 23]. Confirming the results from the preliminary experiments, isolates 145 
10781 and 34350 showed PG in RPMI. The DPL20 and DPL 18 strains were resistant to 146 
caspofungin [3, 23].  147 
Etest MICs were 2-≥8 times higher than MICs observed in the BMD (Table 1). PG was not 148 
observed, the inhibition zone was clear for all clinical isolates. C. albicans and C. 149 
parapsilosis ATCC strains were susceptible to caspofungin, while C. krusei ATCC strain 150 
was intermediate susceptible to caspofungin (Table 1 and Fig. 1) [3, 23]. MIC values for 151 
the two echinocandin resistant isolates were 2 and 32 mg/L (Table 1 and Fig. 1) 152 
 153 
154 
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3.1.2. MIC results in RPMI-1640+50% serum 155 
MIC values in the BMD and Etest methods were 2-16-fold higher in 50% serum when 156 
compared to the MICs obtained in RPMI without serum. MIC ranges of clinical isolates in 157 
50% serum in the BMD and Etest test were 0.125-0.25 and 0.25-0.5 mg/L, respectively. 158 
PG was never observed regardless of the method used (Table 1 and Fig. 1).  159 
 160 
3.1.3. Time kill results in RPMI-1640 and RPMI-1640+50% serum 161 
Maximum log decrease values are shown in Table 2; representative time-kill plots are 162 
shown in Fig. 2. The mean time to achieve 99.9% (T99.9) growth reduction from the 163 
starting inoculums at different caspofungin concentrations are shown in Table 3.  164 
CFU decreases were isolate, concentration and medium dependent. Some isolates showed 165 
re-growth in both media (Table 2). 166 
All isolates grew similarly well in both media; the mean time ranges of controls to growth 167 
1 log in RPMI and 50% serum were 8.66-9.77 and 8.9-10.89 hours, respectively. 168 
In RPMI, caspofungin against 14171 and 35035 isolates produced fungistatic effect, 169 
however, at lower (0.25 and 1 mg/L) concentrations CFU decrease were higher than at 16 170 
and 32 mg/L concentrations (Table 2.). Against isolate 18799, caspofungin was fungicidal 171 
at ≥4 mg/L (Tables 2 and 3). In cases of 5265, 10781 and 34350 isolates typical PG was 172 
observed; fungicidal activity of caspofungin at lower concentrations and fungistatic effect 173 
at 16 and 32 mg/L. The T99.9 values for these three isolates at 1-8 mg/L were short (<12 h, 174 
Table 3). 175 
Caspofungin in 50% serum produced fungistatic effect against isolates 14171, 18799 and 176 
35035 (Fig. 2 and Table 2). Caspofungin killing activity in 50% serum was increased in 177 
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case of all three isolates which showed PG in RPMI-1640; all of these were killed at 4-32 178 
mg/L within 10 hours (Tables 2 and 3).  179 
 180 
3.1.4. Killing rates in RPMI-1640  181 
Caspofungin killing rates (k) were isolate and concentration dependent (Fig. 3). There was 182 
a trend producing higher k values at lower (0.25 or 1 mg/L) concentrations, while k values 183 
were very low at 32 mg/L. For all isolates k values were significantly higher at 1 than at 16 184 
and 32 mg/L (P<0.001). This paradoxical effect was the most prominent in cases of 35035 185 
and 5265 isolates where k values at 1 and 32 mg/L were 0.314 and 0.295 1/h, and 0.021 186 
and 0.011 1/h, respectively. Numerically, the highest k value was observed in case of 187 
10781 isolate, at 1 mg/L (0.961 1/h) (Fig. 3). 188 
 189 
3.1.5. Killing rates in RPMI-1640 plus 50% serum 190 
Killing rate values at 0.25 mg/L were negative in cases of isolates 14171, 35035 and 191 
10781, indicating that growth occurred. For the remaining three isolates k value ranges at 192 
0.25 mg/L were 0.093-0.398 1/h (Fig.3).  193 
Killing rates for 18799, 35035, 5265, 10781 and 34350 isolates were concentration 194 
independent at 1-32 mg/L (p>0.05 for all comparisons). The lowest k value range was 195 
noticed in cases of isolate 18799 (0.085-0.109 1/h), while the highest range was found in 196 
case of isolate 10781 (0.882-0.985 1/h) (Fig. 3).  197 
Isolate 14171 behaved differently. Killing rate values at 1, 4, 8 and 16 mg/L (k value range 198 
was 0.241-0.271 1/h) were significantly higher that at 32 mg/L (k value was 0.126 1/h) 199 
(P<0.05-0.001) (Fig. 3).  200 
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3.1.6. Comparison of the killing kinetics at the same caspofungin concentrations in RPMI-201 
1640 and 50% serum  202 
Killing rates at 0.25 mg/L were higher in RPMI than in 50% serum for all isolates (P<0.05-203 
0.001). In cases of isolates 14171 and 18799 k values were significantly higher at all tested 204 
concentrations in RPMI than in 50% serum, with the exception of 16 mg/L in case of 205 
14171 and 32 mg/L in case of 18799 isolate (P<0.05-0.001).  206 
Caspofungin killing activity at 4-32 mg/L against the remaining isolates increased in 50% 207 
serum when compared to RPMI (P<0.05-0.001) with the exception of the concentration of 208 
8 mg/L in case of 5265, and of 4 and 32 mg/L in case of 34350 isolates. 209 
 210 
3.2. In vivo experiments 211 
All caspofungin doses decreased the fungal tissue burden for all tested clinical isolates 212 
(Fig. 4). One mg/kg caspofungin did not decrease significantly the fungal tissue burden in 213 
cases of isolates 18799, 10781 and 34350; moreover 2 mg/kg also proved to be ineffective 214 
in case of isolate 10781. However, caspofungin doses of 3, 5 and 15 mg/kg proved to be 215 
effective for all isolates (P<0.05 to 0.001). The largest caspofungin dose produced the 216 
highest mean fungal tissue burden decreases in cases of isolates 18799, 5265 and 10781. 217 
Numerically, caspofungin doses of 2, 3 and 2 mg/kg produced the lowest mean fungal 218 
tissue burden in cases of isolates 14171, 35035 and 34350, respectively (Fig. 4). However, 219 
statistically significant differences between the effective doses were never observed.  220 
All doses but 1 mg/kg of caspofungin was effective against the ATCC type strain (P<0.05 221 
to 0.001); there was no significant differences between the effective doses.  Against the 222 
echinocandin resistant strain caspofungin proved to be ineffective regardless of the doses 223 
(data not shown). 224 
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 225 
4. Discussion 226 
Frequency of invasive Candida infections is still increasing; though the non-albicans 227 
Candida species cause increasingly higher proportion of such infections, the most 228 
frequently isolated species is still C. albicans [3, 10-12]. Mean mortality rate is species 229 
dependent, the highest for C. krusei and C. glabrata (50-70%) and the lowest in case of C. 230 
parapsilosis (20-30%) [10-12]. The trend in the mortality did not change radically in the 231 
last decade, despite echinocandins were introduced into the antifungal armamentarium. 232 
Moreover, Lortholary and coworkers [13] noticed that the incidence and mortality of 233 
candidemia significantly increased in intensive care units (ICU), especially in case of C. 234 
albicans and C. glabrata infections. This trend is alarming because echinocandins usage 235 
increased from 4.6% to 48.5% between 2002 and 2010 among ICU patients in France [13]. 236 
Fortunately, the rate of resistance to echinocandins is low worldwide [2-4, 13]. These data 237 
strongly suggest that optimization of antifungal therapy is crucial not only in cases of 238 
fluconazole or echinocandin resistant Candida isolates [2, 3, 10-12] but also in cases of 239 
drug-naïve (wild-type) isolates, which are probably highly susceptible to antifungals [2, 3, 240 
10-13]. 241 
Efficacy of echinocandins correlate with AUC/MIC (area under the concentration curve 242 
per MIC) or Cmax/MIC (peak concentration per MIC), thus larger single or daily doses may 243 
lead to better clinical outcome [1, 2, 4, 5, 21, 28]. Betts and coworkers [29] used three 244 
times higher daily dose (150 mg) than the currently recommended (70 mg on day first 245 
followed by daily 50 mg) caspofungin doses for the treatment of adult patients with 246 
invasive candidasis [2-4, 11, 29]. The daily 150 mg caspofungin produced numerically but 247 
not statistically higher cure rates among patients suffering from invasive C. albicans and 248 
C. parapsilosis infections when compared to the currently recommended dosage strategy, 249 
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without causing severe side effects [29]. As echinocandins are not the first choice in case 250 
of invasive C. parapsilosis infections our attention was drawn to the examination of the 251 
efficacy of higher caspofungin doses against C. albicans [1-4, 11, 16, 21, 29]. 252 
In our study we used six clinical isolates which showed diverse behavior in killing studies 253 
using RPMI as test medium; caspofungin was fungicidal against one isolate, was 254 
fungistatic against two isolates and three isolates showed PG. Decreased activity of 255 
caspofungin at higher (16-32 mg/L) concentrations was confirmed by the lower k values 256 
for all isolates in RPMI. Paradoxical growth is associated with the induction of cell wall 257 
salvage mechanisms by high caspofungin concentrations, which leads to increased amount 258 
of chitin in the cell wall compensating for the decreased β-glucan level [22, 30]. The 259 
detected PG of caspofungin against C. albicans is consistent with the results from other 260 
studies [6, 17, 22, 30].  261 
In concordance with previous results [17, 22, 30], paradoxically decreased activity of 262 
higher concentration of caspofungin was eliminated by 50% serum both in MIC and in 263 
time-kill tests in cases of isolates 5265, 10781 and 34350. Fifty percent serum restored the 264 
killing activity of caspofungin at higher concentrations as revealed by k values. On the 265 
contrary, in case of isolate 14171 the killing rate was higher at 32 mg/L in RPMI than in 266 
50% serum.  267 
The most notable finding of this study is that caspofungin showed concentration-268 
independent activity in 50% serum at 1-32 mg/L against five out of six isolates as 269 
determined by the k values (the exception was again isolate 14171). However, the mean k 270 
value ranges were isolate dependent. We expected that isolates showing higher k values of 271 
caspofungin either in RPMI or in 50% serum will produce better efficacy in a severely 272 
neutropenic murine model, especially at the largest dose [5, 28, 29]. Caspofungin produced 273 
concentration-dependent in vivo efficacy against the clinical isolates and the ATCC type 274 
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strain, i.e. concentrations 3, 5 and 15 mg/kg, but not 1 and 2 mg/kg were uniformly 275 
effective against all tested strains. Moreover, the largest (15 mg/kg) caspofungin dose not 276 
only did not produce significantly better fungal tissue burden decrease than the lower 277 
effective doses 3 and 5 mg/kg, but sometimes the highest numerical decrease was found in 278 
case of lower doses. These in vivo results also confirm that PG has no effect on the in vivo 279 
efficacy of caspofungin against C. albicans [2, 3, 17, 30]. The comparable efficacy of the 280 
safely effective doses is in line with the killing rate results in 50% serum. We have found 281 
similar correlation of in vitro and in vivo efficacy against C. krusei and C. inconspicua 282 
[19]. In agreement with previous findings, caspofungin was ineffective against the 283 
homozygous fks1 mutant strain DPL20 [21, 31]. Thus, our in vivo experiments support the 284 
currently recommended caspofungin dosing strategy (70 mg on day first followed by daily 285 
50 mg), and indicate that dose-escalation has limited benefits against susceptible C. 286 
albicans in the clinic [2-4, 11, 29].  287 
Currently, routine testing or reporting of CLSI and EUCAST MICs of caspofungin for 288 
different Candida species is not recommended, because of the unacceptably high 289 
interlaboratory variability in caspofungin MIC distribution in RPMI (wide MIC ranges 290 
coupled with bimodal MIC distributions) [2, 32]. Caspofungin MIC determination by Etest 291 
is not recommended either. Instead of caspofungin MIC determination both CLSI and 292 
EUCAST recommend testing for micafungin or anidulafungin MIC and these results 293 
should be interpreted for caspofungin susceptibility as well [2, 32]. 294 
In our study we used two types of serum-based susceptibility methods (BMD and Etest) to 295 
determine the MIC values for wild-type and echinocandin resistant strains. In order to 296 
detect PG by Etest, we used RPMI with and without 50% serum [24]; the serum-based 297 
Etest showed good correlation with serum-based BMD, hence, it may be applicable to 298 
determine caspofungin MICs both in case of susceptible and resistant isolates of C. 299 
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albicans (Fig. 1). Although we used low number of wide-type isolates for MIC testing, it is 300 
notable that the MIC range was narrower than in RPMI (Table 1). As serum-based 301 
susceptibility methods have not yet been standardized, they are not recommended currently 302 
for routine susceptibility testing of fungi [14, 23, 33]. The issues to be solved in the future 303 
include the optimal concentration of serum used in the tests, the origin (human or animal 304 
source), as well as the high cost of serum [33]. However, serum from animals (i.e. bovine 305 
serum) may replace human serum in the laboratories, decreasing the cost of serum-based 306 
MIC determinations [14]. Testing higher number of clinical Candida isolates with serum 307 
may provide a sufficient database to determine new epidemiological cutoff values and 308 
possible new clinical break-points for caspofungin against Candida species. 309 
In spite of the extensive work on these antifungal agents, the mortality caused by invasive 310 
fungal infections is still increasing [10, 11, 12], highlighting the need for either new 311 
therapeutic agents, or other novel approaches. In parallel, the increasing resistance to 312 
antibacterial drugs induced research on enhancing the efficacy by modern delivery 313 
methods, e.g. linking the drugs with proteins [34] or incorporating them into nanoparticles 314 
or liposomes [35]. The latter approach also exists in antifungal therapy; three lipid 315 
formulations of amphotericin B are licensed. Research on lipid formulations of other 316 
antimycotics to improve efficacy [36] or to trap drugs at the site of infection [37] as well as 317 
on combination therapy [38] is also available.  318 
319 
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5. Conclusion 320 
Caspofungin activity was uniformly higher at lower than at higher concentrations in RPMI, 321 
with visible PG in MIC test or with prominent fungistatic activity at higher concentrations 322 
in time-kill tests. Fifty percent serum decreased the activity of caspofungin at 0.25 mg/L, 323 
but at 1-32 mg/L we noticed concentration independent killing activity. In a neutropenic 324 
murine model we demonstrated that caspofungin is equally effective against isolates 325 
showing and not showing PG in vitro, and dose escalation did not increase the efficacy of 326 
caspofungin against C. albicans. As serum-based susceptibility testing showed better 327 
predictive value of in vivo results than the currently recommended method, which is in 328 
accordance with the high protein binding of the echinocandin drugs, standardization of a 329 
serum-based protocol for susceptibility testing may be useful. 330 
331 
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Figure legends 483 
 484 
Figure 1 485 
Caspofungin MIC values in case of isolate 10781 as determined by Etest agar diffusion test. MIC values in 486 
RPMI-1640 (left) and RPMI-1640 supplemented with 50% serum (right) were 0.125 and 0.25 mg/L, 487 
respectively. Numbers on the Etest strip refer to caspofungin concentration in mg/L.  488 
 489 
Figure 2 490 
Time-kill curves of caspofungin against Candida albicans isolate 14171 in RPMI-1640 (A) and 50% serum (C), 491 
as well as 10781 isolate in RPMI-1640 (B) and 50% serum (D). The broken lines represent the fungicidal limit 492 
(3-log decrease). 493 
 494 
Figure 3 495 
Killing rates of caspofungin and the corresponding adjusted regression lines (dashed lines) against six Candida 496 
albicans clinical isolates in RPMI-1640 (RPMI) and RPMI-1640 plus 50% serum (Serum). Positive and negative 497 
k values indicate the decreases and increases, respectively, in viable cell numbers. 498 
 499 
Figure 4 500 
Kidney tissue burden of severely neutropenic BALB/c mice infected intravenously with six C. albicans 501 
isolates. Intraperitoneal caspofungin (CAS) (1, 2, 3, 5 and 15 mg/kg) daily treatment was started 24 hours 502 
after the infection. The bars represent the medians. Level of statistical significance compared to the control 503 
population is indicated at P<0.05 (*), P<0.01 (**) and P<0.001 (***). 504 
505 
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Figure 1 506 
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Figure 2 510 
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Figure 3 515 
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Figure 4 519 
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Table 1 Candida albicans isolates and MICs of caspofungin in RPMI-1640 (RPMI) and 523 
RPMI-1640 plus 50 % serum (50% serum) 524 
 525 
 526 
 
Isolates 
Broth microdilution 
MICs (mg/L) 
 
Ratio 
(MICRPMI/
MICserum) 
Etest MICs (mg/L)  
Ratio 
(MICRPMI/
MICserum) 
RPMI 50% serum RPMI 50% serum 
C. albicans  ATCC 10231 0.03 0.5 16x 0.125 0.5 4x 
C. albicans  14171 0.03 0.12 4x 0.125 0.25 2x 
C. albicans  18799 0.06 0.12 2x 0.125 0.5 4x 
C. albicans  35035 0.03 0.25 8x 0.125 0.5 4x 
C. albicans 5265 0.015 0.25 16x 0.03 0.5 16x 
C. albicans  10781 0.03
PG
 0.12 4x 0.12 0.25 2x 
C. albicans  34350 0.015
PG
 0.25 16x 0.12 0.25 2x 
C. albicans  DPL20 4 >32 >8x >32 >32 1x 
C. albicans  DPL18 2 16 8x 2 32 16x 
C. krusei ATCC 6258 0.25 2 8x 0.5 8 16x 
C. parapsilosis ATCC 22019 0.5 1 2x 1 2 2x 
 527 
PG: paradoxical growth 528 
529 
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Table 2 Maximum log changes in log CFU/mL compared to starting inoculum in time-530 
kill studies in RPMI-1640 and RPMI-1640 plus 50 % serum (50% serum) 531 
 532 
Isolate 
 
Media 
Maximum log decreases in CFU in time-killing experiments at the indicated 
caspofungin concentration (mg/L) 
0.25 1 4 8 16 32 
14171 
RPMI-1640 -1.68 -1.12 -1.20 -1.38* -0.69* -0.88 
50% serum -0.90* -1.13 -1.43 -1.38* -1.38 -1.68 
18799 
RPMI-1640 -2.60 -2.78 -3.00 -3.00 -3.00 -3.00 
50% serum -0.89 -1.48 -1.71 -1.27 -1.88 -1.81 
35035 
RPMI-1640 -1.48 -2.68 -2.15 -1.15 -0.02 -0.38 
50% serum -0.83* -1.13 -2.10 -2.60 -1.38 -2.78 
 
5265 
RPMI-1640 -1.97* -3.60 -3.60 -3.60 -1.68* -2.08 
50% serum -1.42* -3.60 -3.60 -3.60 -3.60 -3.60 
 
10781 
RPMI-1640 -3.78 -3.78 -3.78 -2.60 -0.95 -0.16* 
50% serum -1.18* -2.65 -3.78 -3.78 -3.78 -3.78 
 
34350 
RPMI-1640 -3.52 -3.52 -3.52 -3.02 -2.09 -0.39* 
50% serum -1.00 -3.52 -3.52 -3.52 -3.52 -3.52 
*
Re-growth occurred 533 
 534 
535 
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Table 3 Time (hours, h) to reach 99.9% (T99.9) growth reduction from the starting inocula 536 
at different caspofungin concentrations (mg/L) in RPMI-1640 and RPMI-1640 plus 50 % 537 
serum (50% serum). Subtraction signs (-) mean that fungicidal effect was not achieved. 538 
 539 
Isolate 
number 
 
Media 
Time (h) 
0.25 1 4 8 16 32 
14171 
RPMI-1640 - - - - - - 
50% serum - - - - - - 
18799 
RPMI-1640 - - 17.31 14.54 12.56 24.53 
50% serum - - - - - - 
30535 
RPMI-1640 - - - - - - 
50% serum - - - - - - 
 
5265 
RPMI-1640 - 10.18 11.38 11.83 - - 
50% serum - 8.96 8.27 9.68 8.08 8.48 
 
10781 
RPMI-1640 8.82 3.12 4.48 - - - 
50% serum - - 3.06 3.11 3.11 3.27 
 
34350 
RPMI-1640 3.27 3.26 5.17 5.87 - - 
50% serum - 5.08 5.61 4.94 4.85 5.31 
 540 
 541 
 542 
